Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9018799 | 0.93 | LMNA (0.62) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2093177 | 0.86 | MAPT (0.71) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14817806 | 0.86 | ALDH1A1 (0.65) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2093176 | 0.85 | MAPT (0.69) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8334831 | 0.83 | KDM4E (0.69) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6474649 | 0.83 | MAPT (0.67) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3612815 | 0.82 | MEN1 (0.67) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL30623497 | 0.82 | MEN1 (0.67) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10890405 | 0.82 | KDM4E (0.51) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11577296 | 0.82 | LMNA (0.64) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638583-A | Production process of 2-amino-6-nitrobenzoic acid | 山东极地医药科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-110683981-A | Synthesis method of 5-bromo-4-chloro-1-acetyl-3-indophenol | 湖南恒泰生物医药有限公司 | 2020-01-14 | — | — | CN | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| CN-119638583-A | Production process of 2-amino-6-nitrobenzoic acid | 山东极地医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-3169672-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-110683981-A | Synthesis method of 5-bromo-4-chloro-1-acetyl-3-indophenol | 湖南恒泰生物医药有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-4496390-A | WEED-CONTRTOLLING HERBICIDES | MAY & BAKER LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0034945-A2 | N-phenylpyrazole derivatives | MAY & BAKER LIMITED (GB) | 1981-09-02 | — | — | EP | disclosed |
| US-4272531-A | ENZYME INHIBITORS | SMITHKLINE CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| US-4218464-A | 4- and 5-Substituted 2,3-dihydro-1H-isoindoles, pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase | SMITHKLINE CORPORATION (US) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | LMNA 4162/4885POLB 4371/4885MAPT 2666/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | LMNA 4136/4885POLB 4160/4885MAPT 2537/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | LMNA 4162/4885POLB 4371/4885MAPT 2666/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | LMNA 4136/4885POLB 4160/4885MAPT 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.